Lee, Chief Executive Officer of Pacira BioSciences. “Importantly, the use of EXPAREL as a sciatic nerve block in the popliteal fossa affords clinicians additional flexibility in their opioid ...

Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...

“We believe these positive datasets provide the basis for broadening the Exparel label to include both sciatic and femoral nerve blocks, which represents the opportunity to manage pain with a ...

to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa. The approval is supported by data from 2 randomized, double-blind, active ...

FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...

In this study we investigated the efficacy, safety and patient satisfaction of a catheter-based distal sciatic block in CMT patients. The results of this study suggest that peripheral nerve block ...

TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...

The latest nod from the regulatory body has expanded the label of Exparel to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.